Baird Financial Group Inc. Increases Position in Axon Enterprise, Inc $AXON

Baird Financial Group Inc. increased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 158.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,495 shares of the biotechnology company’s stock after purchasing an additional 9,508 shares during the quarter. Baird Financial Group Inc.’s holdings in Axon Enterprise were worth $12,829,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Westside Investment Management Inc. raised its stake in shares of Axon Enterprise by 4.8% during the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after buying an additional 13 shares during the period. CVA Family Office LLC grew its stake in Axon Enterprise by 26.9% in the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 14 shares during the period. STF Management LP increased its holdings in Axon Enterprise by 1.4% in the 2nd quarter. STF Management LP now owns 1,164 shares of the biotechnology company’s stock worth $964,000 after acquiring an additional 16 shares in the last quarter. Hemington Wealth Management raised its position in Axon Enterprise by 70.8% during the second quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 17 shares during the period. Finally, Washington Trust Advisors Inc. raised its position in Axon Enterprise by 44.7% during the second quarter. Washington Trust Advisors Inc. now owns 55 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 17 shares during the period. 79.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

AXON has been the topic of several research analyst reports. Royal Bank Of Canada assumed coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They issued an “outperform” rating and a $860.00 target price on the stock. The Goldman Sachs Group decreased their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Barclays cut their price objective on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Needham & Company LLC reissued a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a report on Wednesday, September 24th. Finally, Wall Street Zen downgraded Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $815.00.

Insider Transactions at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 74 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $536.75, for a total transaction of $39,719.50. Following the completion of the transaction, the chief accounting officer directly owned 14,408 shares in the company, valued at $7,733,494. This trade represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $591.04, for a total value of $5,910,400.00. Following the transaction, the chief executive officer directly owned 3,023,982 shares in the company, valued at approximately $1,787,294,321.28. The trade was a 0.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 32,459 shares of company stock worth $21,049,577 in the last three months. Company insiders own 5.70% of the company’s stock.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $550.95 on Monday. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The company has a 50-day moving average price of $639.29 and a 200 day moving average price of $720.03. Axon Enterprise, Inc has a 12-month low of $469.24 and a 12-month high of $885.91. The stock has a market cap of $43.48 billion, a P/E ratio of 174.35, a PEG ratio of 126.54 and a beta of 1.40.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The business’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same period last year, the company earned $1.45 EPS. Sell-side analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.